Imaging in drug development
Document Type
Article
Publication Date
1-1-2021
Abstract
New, more efficient drug discovery paradigms could fundamentally allow evaluation of a greater number of targets, many of which today have only preclinical face validity, and prevent late-stage testing and extensive human exposure to molecules that have no chance of clinical success. Stopping work on targets and mechanisms that show little early evidence of significant biological benefit allows clinical development resources and energy to be focused on the best candidates and the best-validated hypotheses. Thus the use of biomarkers has the promise to reinvigorate the drug discovery process through improved success rates that help bring useful medicines to patients sooner. This chapter covers the promise and challenges of using imaging biomarkers in drug development with examples from oncology, cardiovascular disease, respiratory disease, bone biology, and central nervous system disorders.
Recommended Citation
Carmichael, O. (2021). Imaging in drug development. Retrieved from https://repository.lsu.edu/clinical_research_pubs/73